Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension
GALT•Pipeline focus and oncology program
The pipeline focus remains belapectin, a galectin-3 inhibitor with Fast Track status, targeting portal hypertension where no approved reversal therapies exist.
The oncology program highlighted belapectin with Keytruda; clinical activity was cited in checkpoint combinations, with FDA clearance to proceed in head and neck cancer.
Belapectin program and NAVIGATE trial results
Galectin Therapeutics outlined plans to file a Phase 3 protocol in Q3 2026 for belapectin in MASH cirrhosis with portal hypertension.
The NAVIGATE Phase 2b/3 trial completed; per-protocol varices incidence fell to 11.3% on belapectin 2 mg vs 22.3% on placebo (p=0.04).
Intent-to-treat composite primary endpoint missed statistical significance (p=0.13 for 2 mg; p=0.55 for 4 mg).
